These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 19246078

  • 1. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 2. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O.
    Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914
    [Abstract] [Full Text] [Related]

  • 3. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
    van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M.
    Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396
    [Abstract] [Full Text] [Related]

  • 4. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.
    Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O.
    Ann Rheum Dis; 2006 Feb; 65(2):191-4. PubMed ID: 16014674
    [Abstract] [Full Text] [Related]

  • 5. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC, Saxne T, Nilsson JA, Geborek P.
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [Abstract] [Full Text] [Related]

  • 6. Specific antibody response after influenza immunization in systemic lupus erythematosus.
    Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D.
    J Rheumatol; 2002 Dec; 29(12):2555-7. PubMed ID: 12465151
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [Abstract] [Full Text] [Related]

  • 8. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 9. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
    Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, França IL, Carvalho JF, Sampaio-Barros PD, Goncalves CR, Borba EF, Timenetsky Mdo C, Precioso AR, Duarte A, Bonfa E, Laurindo IM.
    Ann Rheum Dis; 2011 Dec; 70(12):2144-7. PubMed ID: 21859696
    [Abstract] [Full Text] [Related]

  • 10. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.
    Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, Arad U, Brill A, Paran D, Levartovsky D, Wigler I, Caspi D, Mandelboim M.
    Arthritis Care Res (Hoboken); 2011 Jul; 63(7):1062-7. PubMed ID: 21425247
    [Abstract] [Full Text] [Related]

  • 12. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L, Gyselbrecht L, De Clercq L, Mielants H.
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [Abstract] [Full Text] [Related]

  • 13. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 14. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M.
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [Abstract] [Full Text] [Related]

  • 15. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial.
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [Abstract] [Full Text] [Related]

  • 16. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA.
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [Abstract] [Full Text] [Related]

  • 17. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.
    Vaccine; 2009 Jun 02; 27(27):3561-7. PubMed ID: 19464535
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E, Giménez MD, Mayordomo L, Rodríguez S, González MP, Marenco JL.
    Scand J Rheumatol; 2004 Jun 02; 33(5):323-6. PubMed ID: 15513681
    [Abstract] [Full Text] [Related]

  • 20. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.
    Arthritis Rheum; 2005 Jan 02; 52(1):42-8. PubMed ID: 15641046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.